Heart Failure

SGLT2 inhibitors are now recommended treatments for patients with HF and reduced ejection fraction, according to the 2021 European Society of Cardiology Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.

The SGLT2 inhibitor empagliflozin decreased risk for major renal outcomes in patients with heart failure with reduced ejection fraction but not preserved ejection fraction, according to an analysis of two large randomized controlled trials.

The GUIDE-HF trial of hemodynamic-guided management of HF did not meet its primary endpoint, but analyses limited to the period before the COVID-19 pandemic showed benefit in a broader range of patients than previously demonstrated.

Anticipated results of the EMPEROR-Preserved trial demonstrate that the SGLT2 inhibitor empagliflozin improved clinical outcomes in patients with HF with preserved ejection fraction — the first agent to be shown to do so.

Between 2002 and 2014, methamphetamine-associated HF hospitalizations increased in the U.S., especially in regions in the West Coast, according to a new study published in the Journal of the American Heart Association.

Despite significant improvements in care, HF remains a progressive, complex disease process associated with significant hospital admissions and cost.

Treatment with ferric carboxymaltose in patients with HF, iron deficiency and reduced left ventricular ejection fraction despite a CRT device.

Lung ultrasound-guided ED strategy vs. standard care to assess pulmonary congestion in patients with acute HF.

In a simulation model, the addition of dapagliflozin to guideline-directed medical therapy in patients with HF with reduced ejection fraction improved long-term clinical outcomes while proving cost-effective at current U.S. prices.

In patients with HF requiring cardiac resynchronization therapy, a left ventricular endocardial pacing system conferred favorable clinical response, according to data presented at Heart Rhythm 2021.